Summary:
A Prospective, Randomized, Vehicle-Controlled, Double-Blind, Phase 2 Study to
Assess the Safety, Tolerability, and Efficacy of B244 Delivered as an Intranasal
Spray for Preventive Treatment in Subjects with Episodic Migraine
Qualified Participants Must:
• Males and Females, 18 to 65 years of age
Qualified Participants May Receive:
Compensation for time and travel